Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

RRx-001

Generic Name: RRx-001

Drug Type: Small Molecule

Chemical Formula: C_₅H_₆BrN_₃O_₅

CAS Number: 925206-65-1

Unique Ingredient Identifier: 7RPW6SU9SC

Overview

RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.

Background

RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Phase 1

Terminated

Posted: 2016/06/15

Sponsor:EpicentRx, Inc.

ID:NCT02801097

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Phase 1

Completed

Posted: 2015/08/10

Sponsor:EpicentRx, Inc.

ID:NCT02518958

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Posted: 2015/07/03

Sponsor:EpicentRx, Inc.

ID:NCT02489903

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Phase 2

Terminated

Posted: 2015/05/25

Sponsor:EpicentRx, Inc.

ID:NCT02452970

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

Phase 1

Completed

Posted: 2014/08/13

Sponsor:EpicentRx, Inc.

ID:NCT02215512

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape

2 months ago

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

Endometriosis Clinical Trial Pipeline Shows Promise with 20+ Therapies in Development

4 months ago

The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies.

AdAPT-001, EpicentRx's Oncolytic Virus-Delivered TGFβ Inhibitor, Receives FDA Fast Track Designation for Soft Tissue Sarcoma

6 months ago

The FDA has granted Fast Track designation to EpicentRx's AdAPT-001 for treating recurrent or refractory soft tissue sarcoma (STS).

NLRP3 Inhibitors Show Promise Across Autoimmune, Neurodegenerative, and Metabolic Diseases

6 months ago

The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy